BFEC
CRNX icon

Benjamin F. Edwards & Company’s Crinetics Pharmaceuticals CRNX Stock Holding History

Benjamin F. Edwards & Company’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-200
Closed -$4K – 1824
2022
Q2 		$4K Hold
200
– – ﹤0.01% 1576
2022
Q1 		$4K Hold
200
– – ﹤0.01% 1553
2021
Q4 		$6K Buy
+200
New +$4.93K ﹤0.01% 1475

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Benjamin F. Edwards & Company's CRNX Position: Q3 2022 in Review

Benjamin F. Edwards & Company sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2022, closing a stake of 200 shares — an estimated $4K sold.

Benjamin F. Edwards & Company first reported a position in CRNX in Q4 2021 and held it in 3 quarters. The position peaked at $6K in Q4 2021. 122 funds tracked by Wall St. Rank hold CRNX as of Q3 2022.

  • Benjamin F. Edwards & Company reported no remaining Crinetics Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 200 Crinetics Pharmaceuticals shares in Q3 2022, an estimated $4K.
  • Benjamin F. Edwards & Company first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Benjamin F. Edwards & Company's Crinetics Pharmaceuticals position peaked at $6K in Q4 2021.
  • 122 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2022.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2022, filed 28 Oct 2022.